PYCXF Stock Chart & Stats
$1.66
$0.02(1.77%)
At close: 4:00 PM EDT
$1.66
$0.02(1.77%)
Day’s Range― - ―
52-Week Range$0.67 - $1.83
Previous CloseN/A
Volume500.00
Average Volume (3M)785.00
Market Cap
$1.61B
Enterprise Value$1.21K
Total Cash (Recent Filing)$447.56M
Total Debt (Recent Filing)$624.99K
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Mar 01, 2027EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding983,510,440
10 Day Avg. Volume450
30 Day Avg. Volume785
Financial Highlights & Ratios
PEG Ratio0.70
Price to Book (P/B)1.79
Price to Sales (P/S)0.00
P/FCF Ratio-27.48
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$2.88Price Target Upside73.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.06
Revenue Forecast (FY)$2.85M
Bulls Say, Bears Say
Bulls Say
Low Leverage And Stronger CapitalizationMinimal leverage reduces solvency pressure and gives PYC greater flexibility to continue funding research and development. The increase in assets and equity also indicates added capitalization, providing a stronger financial base than a highly indebted development-stage biotech.
Proprietary RNA Drug PlatformsProprietary discovery and delivery platforms can support repeatable development across multiple RNA therapeutics rather than relying on a single candidate. If the technology translates into successful products, it could create a scalable foundation for a broader pipeline.
Pipeline Addresses High Unmet Medical NeedTargeting diseases with high unmet medical need can support meaningful clinical and commercial opportunity if candidates demonstrate efficacy. A pipeline spanning preclinical and clinical development also provides multiple potential avenues for future value creation.
Bears Say
Persistent Operating LossesPersistent losses show that the current business remains far from self-sustaining and that operating expenses continue to outweigh available revenue. Until candidates progress toward commercial returns, ongoing losses can constrain capital allocation and increase dependence on additional funding.
Accelerating Cash BurnSustained negative operating and free cash flow means PYC is consuming cash rather than financing development internally. The deterioration in FY2026 raises the risk that further external financing will be needed to maintain research and clinical programs.
Revenue Fell To ZeroThe collapse to zero revenue removes current top-line support for the cost base and highlights uncertainty around commercialization or funding-related income. This leaves financial performance especially dependent on future pipeline progress and eventual product or partnership revenues.
PYC Therapeutics Limited News
PYCXF FAQ
What was PYC Therapeutics Limited’s price range in the past 12 months?
PYC Therapeutics Limited lowest stock price was $0.67 and its highest was $1.83 in the past 12 months.
What is PYC Therapeutics Limited’s market cap?
PYC Therapeutics Limited’s market cap is $1.61B.
When is PYC Therapeutics Limited’s upcoming earnings report date?
PYC Therapeutics Limited’s upcoming earnings report date is Mar 01, 2027 which is in 166 days.
How were PYC Therapeutics Limited’s earnings last quarter?
PYC Therapeutics Limited released its earnings results on Aug 28, 2026. The company reported -$0.016 earnings per share for the quarter, beating the consensus estimate of -$0.018 by $0.001.
Is PYC Therapeutics Limited overvalued?
According to Wall Street analysts PYC Therapeutics Limited’s price is currently Undervalued.
Does PYC Therapeutics Limited pay dividends?
PYC Therapeutics Limited does not currently pay dividends.
What is PYC Therapeutics Limited’s EPS estimate?
PYC Therapeutics Limited’s EPS estimate is -0.02.
How many shares outstanding does PYC Therapeutics Limited have?
PYC Therapeutics Limited has 983,510,440 shares outstanding.
What happened to PYC Therapeutics Limited’s price movement after its last earnings report?
PYC Therapeutics Limited reported an EPS of -$0.016 in its last earnings report, beating expectations of -$0.018. Following the earnings report the stock price went down -2.439%.
Which hedge fund is a major shareholder of PYC Therapeutics Limited?
Currently, no hedge funds are holding shares in PYCXF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PYC Therapeutics Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$2.88 (73.29% Upside)
$2.88 (73.29% Upside)
Blogger Sentiment
Bullish
PYCXF Sentiment 100%
Sector Average 62%
Sector Average 62%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
87.23%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
286.58%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
PYC Therapeutics Limited
PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. The company offers VP-001, a drug program, which is in Phase 1 clinical trial for the treatment of retinitis pigmentosa type 11; PYC-001, a drug candidate for treating blinding eye disease named Autosomal Dominant Optic Atrophy, which is in clinical studies; PYC-002, a drug program for the treatment of severe neurodevelopmental disorder named Phelan-McDermid Syndrome, which is in pre-clinical studies; and PYC-003 to treat autosomal dominant polycystic kidney disease, which is in early-stage clinical trials. PYC Therapeutics Limited has academic-industry collaborations with Murdoch University to support drug discovery and development efforts in the field of neurodegenerative disorders. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.
PYCXF Stock 12 Month Forecast
Average Price Target
$2.88
▲(73.29% Upside)
Technical Analysis
Ownership Overview
0.06% Insiders
<0.01% Other Institutional Investors
98.72% Public Companies and
Individual Investors